Penn study finds GLP-1 use associated with lower breast cancer risk; researchers to launch clinical trial

A University of Pennsylvania study found that women taking GLP-1 receptor agonist medications like Ozempic and Wegovy had a 30% lower risk of breast cancer compared to those who did not. Researchers plan to launch a clinical trial to confirm these findings and explore the drugs' potential to prevent cancer recurrence and improve survival rates.